KalVista Pharmaceuticals, Inc. Files 8-K
Ticker: KALV · Form: 8-K · Filed: Aug 21, 2025 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing-update
Related Tickers: KALV
TL;DR
KalVista (KALV) filed an 8-K confirming old names; no new material info.
AI Summary
On August 21, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's former name from Carbylan Therapeutics, Inc. on September 16, 2014, and prior name changes from Carbylan Biosurgery, Inc. in 2013 and 2006. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, Massachusetts.
Why It Matters
This filing primarily serves as a historical record update, confirming past corporate name changes and providing current company details.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not contain new material financial or operational information that would typically impact risk.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- Carbylan Therapeutics, Inc. (company) — Former company name
- Carbylan Biosurgery, Inc (company) — Former company name
- August 21, 2025 (date) — Date of report
- September 16, 2014 (date) — Date of name change
- 2013 (date) — Date of name change
- 2006 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for KalVista Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report current information and confirm historical details, including past corporate name changes.
When was KalVista Pharmaceuticals, Inc. formerly known as Carbylan Therapeutics, Inc.?
KalVista Pharmaceuticals, Inc. was formerly known as Carbylan Therapeutics, Inc. as of September 16, 2014.
What are the principal executive offices of KalVista Pharmaceuticals, Inc.?
The principal executive offices of KalVista Pharmaceuticals, Inc. are located at 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts, 02142.
What is the SEC file number for KalVista Pharmaceuticals, Inc.?
The SEC file number for KalVista Pharmaceuticals, Inc. is 001-36830.
What is the IRS Employer Identification Number (EIN) for KalVista Pharmaceuticals, Inc.?
The IRS Employer Identification Number (EIN) for KalVista Pharmaceuticals, Inc. is 20-0915291.
Filing Stats: 673 words · 3 min read · ~2 pages · Grade level 14.9 · Accepted 2025-08-21 17:00:19
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
Filing Documents
- d928596d8k.htm (8-K) — 25KB
- 0001193125-25-185382.txt ( ) — 136KB
- kalv-20250821.xsd (EX-101.SCH) — 3KB
- kalv-20250821_lab.xml (EX-101.LAB) — 18KB
- kalv-20250821_pre.xml (EX-101.PRE) — 11KB
- d928596d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: August 21, 2025 By: /s/ Brian Piekos Brian Piekos Chief Financial Officer (Principal Financial and Accounting Officer)